Sodium-glucose co-transporter-2 inhibitors as anti-diabetic agents: a review
نویسندگان
چکیده
منابع مشابه
Safety of sodium-glucose co-transporter 2 inhibitors during Ramadan fasting: Evidence, perceptions and guidelines
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new glucose-lowering therapy for T2DM with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. They have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. There is some concern about the safety of using SGLT2 inhibitors in Muslim type 2 diabete...
متن کاملSodium Glucose Co-Transporter 2 (SGLT-2) Inhibitors: A Review Authors
Worldwide, the number of individuals with diabetes is projected to rise from 366 million in 2011 to 552 million by end of 2030. Despite therapeutic advances, the incidence and prevalence of diabetes continues to surge exacting a tremendous economic burden on countries. The major problem with diabetes is that just 50% of population is able to achieve target glycaemic control with available medic...
متن کاملSodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce the complications associated with type 2 diabetes mellitus...
متن کاملsafety of sodium-glucose co-transporter 2 inhibitors during ramadan fasting: evidence, perceptions and guidelines
sodium-glucose co-transporter 2 (sglt2) inhibitors are a new glucose-lowering therapy for t2dm with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. they have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. there is some concern about the safety of using sglt2 inhibitors in muslim type 2 diabete...
متن کاملEuglycemic diabetic ketoacidosis by sodium glucose co-transporter inhibitors: Real but preventable concern
We are thankful for the comments on ‘Sodium glucose co-transporter (SGLT2) inhibitor: Patient safety and clinical importance’, and we appreciate the concern raised for its risk of euglycemic diabetic ketoacidosis (DKA). During clinical development programs for a new drug approval, it is not uncommon that some unexpected safety issues may go unobserved. Interestingly, the incidence of ketoacidos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Basic and Clinical Pharmacology
سال: 2015
ISSN: 2319-2003
DOI: 10.18203/2319-2003.ijbcp20150852